BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Melbourn Scientific Announces Dry Powder Analysis Service at RDD 2012


5/9/2012 10:01:50 AM

May 09, 2012 -- Melbourn Scientific is to extend its portfolio of formulation and analysis services for inhaled product and device development. This follows the introduction of the Freeman Technology FT4 Powder Rheometer, which provides characterisation of powders in order to predict performance.

Derek Solomon, Operations Director at Melbourn Scientific says:

“A key challenge of developing pharmaceuticals for inhalation is creating a formulation that offers both good pharmacologic activity and desirable pharmaceutical properties – fluidity, dispersion, delivery and deposition. “It is becoming more widely understood that powder properties can vary widely with different formulations and this can impact the performance of a DPI. Use of specialist equipment, such as the FT4, makes it possible to characterise the powder and optimise the formulation.”

Particle size determines where product is deposited in the lungs but it is just one of many factors that can impact on the flow properties of a powder.

Most DPI formulations consist of a micronized drug blended with larger carrier particles. When the DPI is actuated the formulation is fluidised and enters the patient’s airways. The inspiratory airflow carries the drug deep into the lungs while the larger carrier particles impact the oropharyngeal surfaces. If the cohesive forces in the powder are too strong the shear of the airflow may not be sufficient to separate the drug from the carrier.

Melbourn Scientific provides support for early stage product development and device development, with teams of formulators and analysts working closely together in teams. Investment in the FT4 means that modifications to formulation can be made and the impacts realised with great precision.

Freeman Technology Operations Manager, Jamie Clayton agrees:

“The FT4 provides an innovative and patented approach to powder testing that quantifies dynamic properties (flow energy, stability, aeration) bulk properties (permeability, compressibility) and shear properties. For the first time this allows sensitive and reliable characterisation of powders with respect to a given process, which helps improve quality control and performance from development through to manufacture.”

The company anticipates that this further investment in leading-edge technology will be a valuable addition to its suite of services.

For media enquiries: Please contact Rachel Holdsworth/Nina Beadle/Claire Lynn, 01954 202789, rebecca@holdsworth-associates.co.uk, www.holdsworth-associates.co.uk

Melbourn Scientific: Martin Westcott, Business Development Manager, Melbourn Scientific Ltd, 01763 261648, martin.westcott@melbournscientific.com, www.melbournscientific.com

About Melbourn Scientific www.melbournscientific.com

Melbourn Scientific, based near Cambridge UK, provides high quality analytical and formulation services to the pharmaceutical and healthcare industry. Clients include major pharmaceutical companies, drug delivery innovators, consultants and virtual companies.

Melbourn Scientific has invested continually in the latest equipment and provides a range of services; formulation and product development; method development and analytical support; stability studies and storage; accelerated feasibility studies, GMP facilities and manufacturing.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES